Media, News
Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF). The company has received US FDA clearance to…
Media, News
Prescient Therapeutics welcomes US FDA allowance of Investigational New Drug application for PTX-100 Phase 2 clinical trial
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is trading higher after receiving a green light from the US Food and Drug Administration (FDA) to proceed with its Phase 2 clinical…
Media, News
Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), which is developing a pipeline of targeted, personalised therapies for cancer, has tapped James McDonnell to lead the…
Media, News
Miles Prince Q&A Update
Reach Markets recently interviewed Professor H. Miles Prince AM – the Principal Investigator of our PTX-100 program – regarding its phase 1b trial and the…
Media, News
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent…
Media, News
Prescient Therapeutics: Current Developments in Cancer Treatment
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific focus on blood cancers that…
Article, Media, News
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the…
Article, Media, News
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull case, Pitt Street Research said the ASX-listed…
Article, Media, News
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a new stage. The company highlighted that PTX is on the…
Media, News
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of…